Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism

Assessment Status Rapid Review Complete
HTA ID -
Drug Rivaroxaban
Brand Xarelto®
Indication Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.
Assessment Process
Rapid review commissioned 20/11/2017
Rapid review completed 21/11/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.